Статья
Применение антигипертензивного препарата комбинированного действия урапидила в клинической практике
В настоящее время комбинированная антигипертензивная терапия рассматривается в качестве основной стратегии лечения больных артериальной гипертензией. К числу эффективных препаратов комбинированного действия относится гибридный препарат урапидил, совмещающий в одной химической структуре центральный антигипертензивный эффект с периферической вазодилатацией. В обзоре обсуждаются результаты клинических и экспериментальных исследований, посвященных анализу антигипертензивного действия урапидила, рекомендованы области применения, а также подчеркнуты хорошая переносимость и безопасность препарата.
1. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Москва 2008; приложение 2 к ж Кардиоваск тер профил: 5-32.
2. Head G.A., Korner P.I., Lewis S.L., et al. Contribubution of noradrenergic and serotonergic neurons to the circulatory effects of centrally acting clonidine and a-methyldopa in rabbits. J Cardiovasc Pharmacol 1983; 5: 945-53.
3. van Zwieten P.A., De Jonge A., Wilffert B., et al. Cardiovascular effects and interaction with adrenoceptors of urapidil. Arch Internat Pharmacod Therapie 1985; 276: 180-201.
4. van Zwieten P.A., Thoolen M.J.M.C., Timmermans P.B.M.W.M. The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine. J Hypertens 1984; 6(Suppl. 11): 28-33.
5. Fozard J.R., Mir A.K. Are 5HT-receptors involved in the antihypertensive effects of urapidil. Br J Pharmacol 1987; 90: 24P
6. Gross G., Hanft G., Kolassa N. Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5HT) binding sites of the 5HT1A. subtype and for α1-adrenoceptor binding sites. Naunyn-Schmiedeberg' s Arch Pharmacol 1987;336:597-601.
7. Giilis R.A., Kellar K.J., Quest J.A., et al. Experimental studies on the neurocardiovascular effects of urapidil. Drugs 1988; 35(Suppl. 6): 20-33.
8. Kolassa N., Beller K.D., Sanders K.H. Involvement of brain 5HT1A-receptors in the hypotensive response to urapidil. Am J Cardiol 1989; 64: 7D-10.
9. Sanders K.H., Beller K.D., Eltze M., et al. Urapidil and some anaglogs with high affinities for serotonin-1A and α1-adrenoceptor binding sites show potent hypotensive activity upon central administration. Curr Opin Cardiol 1989; 4(Suppl. 4): S49-55.
10. van Zwieten P.A., Blauw G.J., van Brummelen P. Pharmacological profile of antihypertensive Drugs with serotonin receptor and a-adrenoceptor activity. Drugs 1990; 40(Suppl. 4): 1-8.
11. Spah F., Grosser K.D., Thieme G. Acute haemodynamic effects of urapidil and nifedipine in hypertensive urgencies and emergencies. Drugs 1990; 40(Suppl. 4): 58-9.
12. Hirschl M.M., Seidler D., Mullner M., et al. Efficacy of different antihypertensive drugs in the emergency department. J Hypertens 1996; 24: 1684-9.
13. Семенова Е.В., Голиков А.П., Рябинин В.А, Лукьянов M.M. Лечение гипертонических кризов с использованием комплексного динамического контроля. ТОП Медицина 1998;2:6-8.
14. Alijotas-Reig J., Bove-Farre I., De Cabo-Frances F., et al. Effectiveness and safety of prehospital urapidil for hypertensive emergencies. Am J Emerg Med 2001; 19: 130-3.
15. Cherney D, Strans Sh. Management of patients with hypertensive urgencies and emergencies. J Gen Intern Med 2002; 17: 937-45.
16. Елагин Р.И. Адренергические средства: альфа-адренобло-каторы. Cons med 2003; 7: 1-6.
17. Rosei E.A., Salvetti M., Farsang С. Лечение осложненных и неосложненных гипертонических кризов. Актуальные вопросы болезней сердца и сосудов 2007; 2: 66-8.
18. Drobinski G., Montalescot G., Fossier J.M., et al. Haemodynamic effects of intravenous urapidil in patients with advanced left ventricular failure. Drugs 1990; 40(Suppl. 4): 63-4.
19. Adnot S., Radermacher P., Andrivet P., et al. Effects of sodium nitroprusside and urapidill on gas exchange and ventilation: perfusion ratios in patients with congestive heart failure. Drugs 1990; 40(Suppl. 4): 65-6.
20. Cazzola M., Spinazzi A., Santangelo G., et al. Acute effects of urapidil on airway response in hypertensive patients with chronic obstructive pulmonary disease. Drugs 1990; 40 (Suppl. 4): 71-2.
21. Задионченко B.C., Погонченкова И.В., Адашева Т.В. Артериальная гипертония при хронической обструктивной болезни легких. Монография. Москва 2005, 243 с.
22. Spah F., Kottmann R., Grosser K.D., et al. Effects of urapidil in patients with mild pulmonary vascular hypertension. Drugs 1990; 40(Suppl. 4): 69-70.
23. Castelhy P.A., Lear S., Lear E., et al. Intrapulmonary shunting during induced hypotension. Anesthesia and Analgesia 1982; 61:231-5.
24. Sivak E.D., Starr N.J., Grave J.W, et al. Extra vascular lung water values in patients undergoing coronary artery bypass surgery. Critic Care Med 1982; 10: 593-6.
25. Mollhoff T., Rosiers P., van Aken H. Urapidil, sodium nitroprusside and nitroglycerin: effects on haemodiynamics, venous admixture and arterial oxygenation after coronary artery bypass grafting. Drugs 1990; 40(Suppl. 4): 73-6.
26. Wallard R., Karp R.B., Reves J.G., et al. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery. A study of hemodynamic and humoral factors. Am J Cardiol 1980; 46: 559-65. '
27. Castelhy P.A.. Lear S., Cottrcll J.E., et al. Intrapulmonary shunting during induced hypotension. Anesthesia and Analgesia 1982;61:231-5.
28. Flaherty J.T., Magee P.A., Gardner T.L., et al. Comparison of intravenous nitroglycerin and sodium nitroprusside for treatment of acute hypertenston developing after coronary artery bypass surgery. Circulation 1982; 65: 1072-7.
29. Jackisch R., Kasakov L., Feuerstein T.J., et al. Effects of urapidil on neurotransmitter release in CNS tissue in vitro. Arch Internat Phamacod Therapie 1987; 285: 5-24.
30. Grant J.A., Scrutton M.C. Interaction of selective a-adrenoceptor agonists and antagonists with human and rabbit blood platelets. Brit J Pharmacol 1980; 71: 121-34.
31. Smith C.C.T., Betteridge D.J., Prichard B.N.C. Platelet in vitro responses to urapidil and prazosin. Drugs 1990; 40(Suppl. 4): 48-51.
32. Hjemdahl P. Plasma catecholamines as markers for sympathoadrenal activity in human primary hypertension. Pharmacol and Toxicol 1988; 63(Suppl. 1): 27-31.
33. Emanuelli G., Anfossi G., Lanzio M., et al. Influence of urapidil on in vitro platelet responses to adrenaline and other aggregating agents. Pharmacol Res Communicat 1988; 20: 883-99.
34. Prehn J.H., Welsch M., Backhauss, et al. Effect of serotonergic drugs in experimental brain ischemia. Evedence for a protective role of serotonin in cerebral ischemia. Brain -Res 1993; 63: 10-20.
35. Grossman E, Hironi A.N., Messerli F.H. Comparative tolerability profile of hypertensive crisis treatments. Drug Saf 1998;19:99-122.
36. Migneco A., Ojetti V., De Lorenzo A., et al. Hypertinsive crises: diagnosis and management in the emergency room. Eur Rev Med Pharmarcol Sciences 2004; 8: 143-52.
37. Morrell D.F. Качественная управляемая гипотензия. Ж. Мед неотл сост 2007; 3: 127-34.
38. Mancia G. Haemodynamic effects of the multiple action antihypertensive drug urapidil. Drugs 1990; 40(Suppl. 4): 14-29.
39. Takeda T., Kaneko Y., Shionoiri H., et al. Urapidil in patients with severe hypertension and in long treatment. J Hypertens 1988; 6(Suppl. 2): S37-42.
40. Leonetti G., Terzoli L., Zanchetti A. Systemic haemodynamic and humoral changes during urapidil treatment in hypertensive patients. J Hypertens 1988; 6(Suppl. 2): S25-9.
41. Boyer E.W., Shannon M. The serotonin syndrome. N Engl J Med 2005; 352(11): 1112-20.
42. Beller K.-D., Boer R., Sanders K.H., et al. Blockade of α1-adrenoceptors favourable in hypotension induced by stimulation of serotonin1A receptors in conscious dogs? Drugs 1990; 40(Suppl. 4): 38-41.
43. Spah F., Grosser K.D., Thieme G. Acute haemodynamic effects of urapidil and nifedipine in hypertensive urgencies and emergencies. Drugs 1990; 40(Suppl. 4): 58-9.
44. Distler A., Haerlin R., Hilgenstock G., et al. Clinical aspects of antihypertensive therapy with urapidil: comparison with hydrochlorthiazide. Drugs 1990; 40(Suppl. 4): 21-7.